指南与共识乳腺癌放疗头颈部肿瘤放疗胸部肿瘤放疗

ASTRO共识:放疗计划剂量约束DVH汇编

Dose-Volume Histogram Compendium of Dose Constraints for Treatment Planning: An ASTRO Consensus Paper.
指南 / 共识 · Pract Radiat Oncol · 2026-01-22

该ASTRO共识文件汇总了VA与ASTRO为放疗质量监测开发的乳腺、头颈、肝、肺、前列腺和直肠癌的DVH剂量约束表,基于常用分割方案、临床数据和多中心试验,采用改良Delphi法(≥75%同意)达成共识,旨在支持剂量学决策和标准化。

要点

  • 汇编覆盖乳腺、头颈、肝、肺、前列腺和直肠癌的常用分割方案DVH约束。
  • 约束值优先采用经临床数据验证或多中心试验使用的剂量学指标。
  • 共识采用改良Delphi法,预设≥75%同意阈值,未达标内容删除或修订。

核心结论

  • 该DVH汇编是VA与ASTRO质量监测工作的成果,提供实用且反映一般实践和既定方案的默认约束,支持标准化并改善治疗计划与放疗实施质量。

研究设计与样本

  • 由VA与ASTRO组织疾病部位专家组制定DVH表,覆盖乳腺、头颈、肝、肺、前列腺和直肠癌的常用剂量/分割方案,经小组讨论和投票达成共识。

主要发现

  • 剂量约束优先纳入经既往临床数据验证及正在进行的多中心试验使用的剂量学值,并在表中列出参考文献。
  • 在特定约束数据缺乏时,由疾病部位专家组讨论并商定适当的临床指导。
  • 共识采用改良Delphi法,通过保密调查以预设≥75%评分者同意或强烈同意为阈值,未达阈值内容删除或修订,重大修订返回专家组复审、批准和最终共识投票。

关键数值与推荐

  • 共识阈值:改良Delphi法预设≥75%的评分者同意或强烈同意。
  • 覆盖病种:乳腺、头颈、肝、肺、前列腺和直肠癌。

临床怎么用

  • 临床可将该DVH汇编作为默认约束参考,支持医生在剂量学治疗计划中的决策,并促进外照射放疗DVH指标的标准化。

局限性

  • 不同剂量计算方法产生不同数据,需持续努力协调不一致之处。
  • 毒性报告存在广泛差异,标准化努力有待未来试验数据加深知识。
  • 目标体积和正常组织的剂量目标与约束仍需优化,未来计划扩展至其他疾病部位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This dose-volume histogram (DVH) compendium shares the knowledge and resources compiled by disease-site experts during an immense undertaking by the Veterans Affairs (VA) and American Society for Radiation Oncology (ASTRO) to develop performance indicators for radiation therapy as part of quality surveillance. The guidance for breast, head and neck, liver, lung, prostate, and rectal cancers supports physician decision-making during dosimetric treatment planning, directs the reader to additional resources, and contributes to the evolution of DVH metrics for external beam radiation therapy. METHODS AND MATERIALS: DVH tables were developed for each disease site relating to the most common dose/fractionation regimens used in VA and non-VA radiation oncology centers nationwide. Dosimetric values with validation through prior clinical data and those used in ongoing multisite trials were prioritized, with references listed in the tables. In scenarios with a paucity of data for specific constraints, the disease-site panels discussed and agreed on appropriate clinical guidance. After panel discussion, each metric was voted on to obtain panel consensus. Panel consensus was evaluated with a modified Delphi approach using a prespecified threshold of ≥75% of raters who agree or strongly agree to establish consensus via a confidential survey. Where the content did not meet this threshold, it was removed or revised. Significant revisions went back to the full disease-site panel for review, approval, and a final consensus vote. RESULTS: The dose constraints are the result of quality measure development between the VA and ASTRO. They represent the body of work thus far, with the goal of expanding future resources to include other disease sites. There is still work to be done to optimize dose goals and constraints for target volumes and normal tissues. Different methodologies for calculating doses have produced varying data, and ongoing efforts will harmonize the lack of concordance where possible. Wide variation when reporting on toxicities and efforts to standardize provide an opportunity for future trial data to add to the depth of knowledge. This DVH compendium is pragmatic and reflective of general practice and established treatment regimens. Having accessible default constraints supports standardization and will help improve the quality of treatment planning and radiation delivery for all patients.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Puckett LL, Apisarnthanarax S, Ballas LK, et al. Dose-Volume Histogram Compendium of Dose Constraints for Treatment Planning: An ASTRO Consensus Paper. Pract Radiat Oncol. 2026. PMID: 41569222. doi:10.1016/j.prro.2025.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。